continu
spread
highli
pathogen
avian
influenza
hpai
viru
underscor
import
effect
antivir
approach
potent
broadreact
human
monoclon
antibodi
mab
show
great
potenti
use
either
therapeut
purpos
basi
vaccin
develop
antigen
epitop
neutral
mechan
fine
character
studi
first
demonstr
target
novel
conformationdepend
epitop
globular
head
region
hemagglutinin
ha
select
mimotop
random
peptid
librari
combin
comput
algorithm
sitedirect
mutagenesi
epitop
map
three
conserv
discontinu
site
iiii
locat
close
threedimension
structur
ha
found
human
mab
effici
block
virusreceptor
bind
postattach
step
fab
fragment
exert
postattach
inhibit
consist
could
inhibit
hamedi
cellcel
membran
fusion
dosedepend
manner
block
acquisit
phinduc
proteas
sensit
result
suggest
neutral
mechan
simultan
block
viral
attach
receptor
host
cell
interf
ha
conform
rearrang
associ
membran
fusion
present
data
provid
critic
inform
develop
novel
antivir
therapeut
vaccin
hpai
viru
highli
pathogen
avian
influenza
hpai
virus
continu
spread
among
poultri
frequent
broken
speci
barrier
transmit
human
februari
confirm
human
infect
countri
fatal
rate
alarm
consequ
pandem
could
catastroph
therefor
mani
effort
focus
develop
effect
therapeut
vaccin
prepared
neutral
antibodybas
strategi
particularli
explor
viral
hemaglutinin
ha
surfac
glycoprotein
influenza
virus
respons
bind
cell
receptor
also
primari
target
neutral
antibodi
initi
synthes
precursor
polypeptid
subsequ
cleav
cellular
proteas
disulfidelink
subunit
ntermin
subunit
form
globular
head
region
contain
receptorbind
site
rb
wherea
membran
anchor
subunit
form
helixrich
stem
contain
rel
conserv
fusion
peptid
ha
protein
influenza
virus
evolv
great
genet
divers
classifi
distinct
subtyp
howev
subtyp
fine
character
respect
antigen
structur
earli
locat
structur
ha
epitop
first
character
threedimension
model
subtyp
four
antigen
site
demonstr
b
c
fifth
e
later
describ
structur
use
map
antigen
site
subtyp
ha
antigen
map
greater
detail
crystal
structur
report
promin
antibodi
bind
epitop
ha
locat
exclus
area
correspond
antigen
site
b
ha
antigen
site
sa
ha
recent
kaverin
et
al
demonstr
ha
antigen
structur
recent
hpai
isol
differ
substanti
lowpathogen
strain
describ
earlier
rapidli
evolv
also
noteworthi
previou
epitop
map
ha
protein
larg
base
viru
escap
mutant
select
mous
monoclon
antibodi
mab
might
precis
predict
antigen
epitop
recogn
human
immun
system
appar
success
passiv
immunotherapi
patient
convalesc
plasma
emphas
import
human
antibodi
fight
influenza
also
spark
develop
neutral
human
mab
antivir
agent
variou
approach
importantli
human
mab
also
use
map
antigen
epitop
ha
stimul
humor
immun
respons
natur
infect
influenza
virus
thu
serv
ideal
basi
vaccin
develop
recent
sun
et
al
gener
two
human
mab
screen
phage
display
librari
deriv
recov
patient
infect
highli
pathogen
virus
previou
studi
show
broadspectrum
activ
passiv
immun
could
effici
protect
mice
lethal
viru
infect
studi
focus
character
antigen
epitop
neutral
mechan
data
demonstr
target
novel
conserv
conformationdepend
epitop
locat
globular
head
region
ha
exert
neutral
activ
simultan
block
viral
attach
cell
receptor
interf
ha
conform
rearrang
associ
membran
fusion
previou
studi
conclud
human
mab
target
linear
epitop
within
sequenc
iipksswss
global
head
region
ha
better
locat
epitop
residu
synthes
set
overlap
peptid
cover
full
length
ha
use
peptidebas
elisa
fig
disappointedli
react
peptid
contain
iipksswss
sequenc
overlap
nonoverlap
peptid
react
strongli
recombin
ha
protein
fig
result
impli
epitop
could
simpli
locat
within
iipksswss
motif
therefor
test
reactiv
dttreduc
ha
comparison
nativ
ha
fig
show
disulfid
bond
reduct
ha
protein
could
complet
abolish
bind
serv
control
antibodi
recogn
conformationdepend
epitop
react
nativ
reduc
ha
similarli
sever
control
antibodi
recogn
linear
epitop
within
react
nativ
reduc
ha
protein
result
indic
direct
disulfid
bonddepend
conform
epitop
express
subunit
sought
deciph
bind
site
select
mimotop
random
peptid
phage
display
librari
previous
use
map
conformationdepend
mab
round
pan
phage
clone
isol
amino
acid
sequenc
peptid
determin
fig
specif
rel
affin
bind
peptid
test
elisa
describ
total
select
differ
mimotop
could
find
appar
consensu
sequenc
common
sequenc
motif
deduc
epitop
ha
residu
therefor
use
two
comput
method
mapitop
predict
epitop
search
algorithm
preferenti
identifi
discontinu
bcell
epitop
base
structur
protein
antigen
shown
fig
mapitop
predict
total
residu
predict
residu
predict
residu
exclus
locat
global
head
region
subunit
notabl
two
patch
residu
predict
program
suggest
involv
two
site
bind
identifi
epitop
residu
critic
bind
gener
panel
ha
mutant
carri
singl
amino
acid
substitut
tabl
wildtyp
wt
mutat
ha
protein
transient
express
surfac
cell
transfect
reactiv
ha
mutant
examin
ifa
fac
assay
result
shown
tabl
fig
control
express
mutat
affect
bind
abil
human
mab
direct
subunit
promin
substitut
alanin
complet
abolish
bind
ha
express
cell
surfac
substitut
residu
result
dramat
loss
reactiv
result
verifi
residu
critic
site
bind
addit
mutat
also
substanti
reduc
reactiv
express
ha
fac
assay
remain
substitut
signific
effect
bind
control
antibodi
therefor
three
discontinu
site
design
site
site
ii
site
iii
like
involv
epitop
structur
epitop
residu
adjac
tip
membranedist
globular
domain
ha
monom
close
proxim
receptorbind
domain
fig
importantli
amino
acid
highli
conserv
among
divers
clade
subclad
underli
broadspectrum
activ
cell
entri
influenza
virus
mediat
ha
protein
two
step
first
ha
protein
bind
cell
receptor
result
endocytosi
viru
host
second
viral
membran
fuse
endosom
membran
releas
viral
rna
host
cell
explor
mechan
neutral
first
perform
experi
know
whether
mab
inhibit
receptorbind
step
shown
fig
viru
bind
inhibit
assay
indic
could
effici
inhibit
hamedi
viru
bind
mdck
cell
appar
inhibit
dosedepend
manner
high
medium
low
fig
show
inhibit
curv
ic
mgml
howev
fab
fragment
inhibitori
activ
expect
two
control
mab
could
inhibit
virusreceptor
bind
known
reactiv
test
ha
target
conserv
epitop
subunit
studi
whether
inhibit
viru
attach
target
cell
postattach
neutral
assay
ha
pseudovirus
allow
absorb
mdck
cell
unbound
virus
wash
differ
concentr
antibodi
ad
determin
prevent
attach
viru
enter
target
cell
membran
fusion
shown
fig
igg
fab
molecul
mediat
postattach
inhibit
dosedepend
manner
inhibit
ha
pseudovirus
mean
ic
valu
mgml
respect
control
antibodi
inhibitori
activ
attach
virus
consist
previou
report
reveal
postattach
neutral
assay
might
inhibit
receptorbind
step
also
membran
fusion
step
directli
evalu
whether
case
perform
two
cell
fusion
assay
describ
materi
method
first
fusion
assay
vero
cell
transfect
ha
induc
fusion
lowph
presenc
absenc
control
mab
shown
fig
inhibit
hamedi
cellcel
fusion
second
fusion
assay
demonstr
could
inhibit
fusion
hatransfect
effector
cell
mdck
target
cell
typic
doserespons
curv
control
effect
system
receptorbind
subunit
specif
mab
could
also
inhibit
hamedi
cell
membran
fusion
sought
ascertain
mechan
proteas
suscept
assay
ha
protein
expos
lowph
trigger
conform
chang
acquir
sensit
cleavag
trypsin
convincingli
lowph
treat
ha
could
complet
digest
trypsin
absenc
fab
fragment
lane
fig
howev
format
antibodi
abl
protect
ha
degrad
proteas
lane
fig
result
suggest
bind
fab
fragment
block
ha
undergo
conform
chang
thu
render
resist
proteolysi
newlyisol
human
mab
possess
potent
broad
neutral
activ
highli
pathogen
influenza
viru
vivo
protect
challeng
viru
highlight
potenti
applic
therapeut
antibodi
basi
vaccin
develop
case
character
antigen
epitop
mechan
neutral
key
step
present
studi
first
demonstr
epitop
conformationdepend
consist
three
discontinu
site
site
compris
three
amino
acid
residu
site
ii
site
iii
compris
two
amino
acid
structur
ha
epitop
residu
close
locat
tip
membranedist
globular
head
ha
neighbor
receptorbind
domain
compris
color
red
fig
interestingli
although
region
highli
variabl
epitop
participatori
residu
highli
conserv
among
divers
clade
subclad
believ
conserv
could
provid
basi
antibodi
exert
broadspectrum
activ
obvious
present
result
differ
previou
data
report
sun
et
al
author
consid
direct
linear
epitop
base
reactiv
westernblot
assay
epitop
locat
within
amino
acid
sequenc
iipksswss
base
mutagenesi
analysi
western
blot
assay
use
recombin
protein
transfect
cell
sampl
repeatedli
react
ha
protein
gel
data
shown
gener
view
simplest
way
determin
whether
epitop
conform
linear
immunoblot
sdspage
antibodi
still
bind
protein
denatur
epitop
unlik
highli
conform
howev
protein
renatur
occur
sd
gel
electrophoresi
electroblot
may
result
epitop
refold
particular
posit
reaction
immunoblot
also
achiev
nonlinear
epitop
react
portion
rel
close
proxim
experi
panel
mous
mab
spike
protein
sarscov
react
antigen
immunoblot
epitop
conformationdepend
therefor
epitop
might
case
steric
residu
three
site
could
readili
refold
shortrang
interact
keep
local
conform
epitop
could
refold
ha
protein
treat
reduc
reagent
follow
block
reactiv
site
thu
result
loss
reactiv
elisa
well
contradict
previou
conclus
could
recogn
synthes
peptid
contain
overlap
propos
linear
epitop
sequenc
iipksswss
taken
togeth
data
strongli
suggest
conformationdepend
epitop
therefor
decid
map
contact
residu
surfac
ha
tridimension
structur
use
random
vaccin
consid
effici
strategi
combat
influenza
viru
contin
antigen
drift
occasion
antigen
shift
significantli
hamper
develop
univers
influenza
vaccin
mani
year
consider
effort
made
character
antigen
epitop
ha
protein
much
avail
inform
pertain
antibodi
gener
mice
rather
human
frequent
occurr
highli
pathogen
human
case
recent
outbreak
novel
swinelik
human
influenza
viru
promot
explor
naturaloccur
human
antibodi
therapeut
vaccin
design
recent
year
number
human
mab
virus
gener
either
immort
human
memori
b
cell
obtain
patient
recov
diseas
combin
antibodi
librari
technolog
shown
human
antibodi
possess
broadspectrum
activ
crosssubtyp
reactiv
virus
highli
effect
suppress
viru
experiment
infect
anim
administ
prophylact
therapeut
importantli
antigen
character
newlyisol
human
mab
identifi
novel
neutral
epitop
ha
protein
provid
intrigu
insight
univers
influenza
vaccin
develop
best
exampl
human
mab
possess
broadli
neutral
activ
direct
highli
conserv
epitop
subunit
also
impress
epitop
overlap
two
epitop
recogn
human
mab
isol
surviv
hpai
vietnam
recogn
conform
epitop
contain
residu
qiip
easl
narrow
clade
neutral
rang
recogn
conform
epitop
contain
residu
sw
ynnt
rel
broader
crossclad
neutral
former
prepar
manuscript
new
human
mab
neutral
protect
activ
report
hu
et
al
isol
surviv
patient
infect
china
map
conform
epitop
contain
residu
given
neutral
human
mab
isol
differ
surviv
patient
independ
laboratori
react
overlap
epitop
close
locat
similar
region
surfac
ha
structur
believ
epitop
repres
immunodomin
site
natur
infect
use
immunogen
design
elicit
broadspectrum
neutral
antibodi
highli
pathogen
virus
antigen
epitop
influenza
viru
explor
hotspot
mechan
neutral
antibodi
paid
much
less
attent
actual
aspect
import
dissect
structur
function
ha
protein
thu
develop
immunotherapeut
vaccin
influenza
studi
first
demonstr
could
block
hamedi
viru
attach
postattach
step
show
direct
inhibit
hamedi
cellcel
fusion
acquisit
phinduc
proteas
sensit
data
suggest
neutral
viru
inhibit
receptorbind
also
membran
fusion
word
neutral
mechan
occur
simultan
may
surpris
know
mab
block
two
key
step
vial
entri
infect
previou
studi
demonstr
analyz
immuofluoresc
assay
ifa
assay
wt
ha
mutant
transient
express
cell
transfect
immunostanin
control
mab
final
concentr
mgml
specif
mous
mab
behav
similarli
although
specif
concentrationdepend
event
interestingli
recent
studi
report
mous
mab
abl
block
interact
ha
receptor
block
viru
entri
postattach
step
consist
shown
prevent
phmediat
conform
chang
ha
inde
neutral
influenza
virus
highli
complex
multifacet
govern
factor
includ
viru
strain
antigen
epitop
antibodi
affin
concentr
cell
use
notabl
fab
fragment
could
inhibit
receptorbind
step
concentr
igg
molecul
fig
sharp
contrast
could
effici
block
membran
fusion
step
evidenc
potent
inhibit
viral
entri
cell
attach
fig
ha
acquisit
phinduc
proteas
sensit
fig
previou
studi
establish
fab
neutral
virus
inhibit
fusion
activ
differ
igg
hand
fab
neutral
inhibit
viru
attach
mechan
neutral
igg
complex
occur
simultan
fusion
inhibit
attach
inhibit
compar
mab
mab
neutral
viru
mechan
inhibit
membran
fusion
activ
exclus
summari
signific
present
studi
threefold
first
show
direct
novel
conserv
conform
epitop
globular
head
ha
protein
second
epitop
residu
fine
map
three
discontinu
site
close
neighbor
receptorbind
domain
third
neutral
viru
mechan
inhibit
receptorbind
membran
fusion
simultan
data
multipl
implic
develop
effect
immunotherapeut
vaccin
highli
pathogen
viru
gener
initi
character
describ
previous
recombin
igg
fab
fragment
produc
insect
cell
sino
biolog
inc
beij
human
mab
similarli
produc
insect
cell
accord
public
mous
mab
obtain
sino
biolog
inc
human
antihiv
fab
gener
laboratori
use
control
set
overlap
peptid
span
entir
sequenc
ha
protein
strain
vietnam
ha
pseudovirus
preincub
test
antibodi
overnight
subsequ
ad
mdck
cell
hour
unbound
virus
wash
amount
bound
virus
quantifi
bind
express
percentag
read
obtain
absenc
antibodi
ab
set
fab
fragment
control
mab
inhibit
pseudoviru
bind
mdck
cell
indic
concentr
b
fab
fragment
inhibit
pseudoviru
bind
dosedepend
manner
elisa
reactiv
human
mous
mab
variou
ha
antigen
determin
elisa
briefli
mgml
recombin
mgml
peptid
use
coat
microtit
plate
costar
corn
ny
carbon
buffer
ph
overnight
plate
block
bovin
serum
albumin
bsa
h
rt
wash
tween
pbst
test
human
mous
mab
dilut
mgml
ad
well
incub
h
follow
three
wash
pbst
bound
antibodi
detect
hrpconjug
goat
antihuman
mous
igg
sigma
aldrich
h
follow
three
wash
reaction
visual
addit
tmb
substrat
sigma
stop
addit
h
absorb
nm
measur
elisa
plate
reader
biorad
determin
effect
disulfid
bond
reduct
bind
antiha
mab
elisa
plate
coat
recombin
concentr
mgml
treat
dithiothreitol
dtt
concentr
mm
h
follow
wash
plate
well
treat
mm
iodoacetamid
h
wash
standard
elisa
perform
describ
random
phage
display
librari
wherein
display
peptid
express
fuse
n
terminu
giii
protein
purchas
new
england
biolab
beverli
affin
select
phage
clone
librari
figur
postattach
neutral
fab
fragment
ha
pseudovirus
allow
attach
monolay
mdck
cell
hour
unbound
virus
wash
test
antibodi
ad
monolay
hour
cell
incub
hour
luciferas
activ
cell
lysat
determin
viral
entri
express
percentag
read
obtain
absenc
antibodi
ab
set
fab
well
inhibit
viral
entri
indic
concentr
b
fab
inhibit
pseudoviru
entri
dosedepend
manner
perform
accord
manufactur
instruct
brief
microtit
well
coat
mgml
ml
nahco
buffer
ph
overnight
coat
well
block
bsa
nahco
buffer
least
h
wash
time
tbst
tb
phage
librari
ad
coat
well
incub
room
temperatur
rt
h
wash
plate
time
tbst
bound
phage
elut
glycinehcl
ph
contain
mgml
bsa
neutral
trishcl
ph
elut
phage
amplifi
infect
logphag
escherichia
coli
concentr
polyethylen
glycol
peg
precipit
phage
titer
submit
second
round
select
three
round
select
select
phage
clone
identifi
singlestrand
dna
sequenc
target
specif
confirm
phage
elisa
briefli
microtit
well
coat
ml
mgml
block
bsa
affinityselect
phage
ad
two
webavail
comput
program
mapitop
appli
predict
epitop
base
select
peptid
mimotop
random
phage
display
librari
algorithm
mapitop
base
assumpt
epitop
separ
sever
amino
acid
pair
aap
contribut
bind
antibodi
entir
set
peptid
enrich
aap
mimic
genuin
epitop
promis
aco
ant
coloni
optim
algorithm
propos
search
match
path
antigen
surfac
respect
queri
mimotop
motif
tool
valid
map
conformationdepend
epitop
base
affinityselect
mimotop
plasmid
encod
fulllength
ha
construct
use
templat
panel
ha
mutant
tabl
gener
sitedirect
mutagenesi
use
quikchang
xl
kit
stratagen
la
jolla
ca
primer
use
construct
ha
mutant
design
synthes
accord
manufactur
instruct
introduc
mutat
verifi
dna
sequenc
figur
inhibit
phinduc
conform
chang
ha
recombin
ha
protein
incub
without
fab
b
h
mixtur
either
held
ph
lane
chang
ph
lane
h
ph
restor
trypsin
mgml
ad
detect
acquisit
phinduc
proteas
suscept
lane
sampl
analyz
western
blot
molecular
marker
given
left
reactiv
wildtyp
wt
ha
ha
contain
mutat
measur
flow
cytometri
briefli
cell
transient
transfect
specif
plasmid
transfect
cell
harvest
h
transfect
wash
two
time
pb
contain
bsa
control
mab
ad
cell
final
concentr
mgml
incub
h
cell
wash
three
time
pb
contain
bsa
incub
fitcconjug
goat
antihuman
antimous
igg
sigma
h
dark
three
wash
cell
resuspend
cold
pb
analyz
becton
dickinson
facscalibur
becton
dickinson
franklin
lake
nj
plasmid
encod
ha
wt
mutant
transient
express
cell
transfect
hour
cell
directli
stain
well
briefli
cell
first
fix
paraformaldehyd
pb
ph
min
rt
follow
three
wash
pb
cell
incub
bsa
pbst
min
block
unspecif
bind
antibodi
control
mab
ad
cell
final
concentr
mgml
incub
rt
h
humidifi
chamber
wash
bound
antibodi
detect
use
fitcconjug
antihuman
antibodi
observ
immunofluoresc
microscop
viru
bind
assay
perform
use
ha
pseudotyp
hiv
virus
describ
previous
briefli
ha
pseudovirus
gener
cotransfect
cell
plasmid
plasmid
encod
na
protein
backbon
plasmid
encod
envdefect
luciferaseexpress
genom
pseudovirus
first
incub
test
antibodi
fab
fragment
control
mab
dilut
dmem
contain
bsa
overnight
mdck
cell
seed
plate
grew
h
monolay
block
dmem
contain
bsa
h
mixtur
pseudovirus
antibodi
inocul
onto
mdck
cell
incub
h
cell
rins
four
time
pb
contain
bsa
remov
unbound
virus
cell
lyse
ml
dmem
use
freezethaw
method
amount
cellbound
virus
presenc
absenc
antibodi
quantifi
elisa
kit
vironostika
antigen
microelisa
system
biomerieux
percent
inhibit
inhibitori
concentr
ic
calcul
postattach
assay
perform
previous
describ
briefli
hapseudovirus
inocul
onto
mdck
monolay
plate
h
unbound
virus
remov
wash
cold
pb
test
antibodi
serial
dilut
ad
monolay
h
antibodi
remov
wash
fresh
dmem
ad
monolay
incub
h
infect
luciferas
activ
cell
measur
use
luciferas
assay
system
promega
madison
accord
manufactur
instruct
percent
inhibit
ic
calcul
cell
fusion
inhibit
assay
perform
describ
previous
brief
vero
cell
grown
confluent
plate
transfect
plasmid
mg
total
dna
per
well
use
lipofectamin
invitrogen
accord
instruct
manual
hour
transfect
cultur
medium
supplement
mg
ml
control
mab
h
wash
three
time
pb
ph
cell
incub
lowph
fusioninduc
buffer
mm
nacl
mm
hepe
adjust
ph
min
return
standard
cultur
medium
hour
final
cell
fix
polyoxymethylen
stain
crystal
violet
min
quantit
analyz
inhibitori
effect
hadriven
cellcel
fusion
sensit
assay
adapt
previou
studi
briefli
effector
cell
seed
plate
cell
per
well
transfect
combin
plasmid
encod
herp
simplex
viru
transactiv
fuse
dna
bind
domain
saccharomyc
cerevisia
transcript
factor
parallel
mdck
target
cell
transfect
plasmid
encod
luciferas
report
gene
control
promot
contain
five
bind
site
day
transfect
effector
cell
incub
variou
concentr
test
antibodi
dilut
serumfre
medium
optimem
h
wash
effector
cell
treat
lowph
fusion
induc
buffer
min
ad
target
cell
cocultur
addit
h
cell
lyse
cell
cultur
lysi
buffer
luciferas
activ
measur
luciferas
assay
system
promega
percent
inhibit
ic
calcul
proteas
suscept
assay
adapt
previou
studi
brief
mg
ha
protein
incub
fab
h
neutral
mixtur
kept
ph
lower
ph
addit
hcl
incub
h
ph
mixtur
restor
neutral
ph
addit
tri
ph
chang
ha
lowph
conform
detect
incub
trypsin
mgml
h
reaction
stop
addit
nonreduc
sd
load
buffer
analyz
western
blot
briefli
digest
mixtur
fraction
sdspage
reduc
condit
separ
protein
electrotransf
immobil
pvdf
membran
block
nonfat
milk
pb
overnight
membran
incub
mous
antiha
mab
specif
h
follow
wash
pb
hrpconjug
goat
antimous
igg
ad
incub
rt
h
membran
wash
incub
ecl
reagent
pierc
